Interestingly, one of these studies showed a higher expression of IL13Rα2 on stem-like vs. differentiated glioma populations, indicating that IL13Rα2-directed immunotherapeutic approaches could be useful for eradicating therapeutically resistant glioblastoma stem cell (GSC) populations (62). This evidence concerns the gene IL13RA2 and glioma.